Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease

Drug repurposing has been shown to bring safe medications to new patient populations, as recently evidenced by the COVID-19 pandemic. We investigated whether we could use phenotypic screening to repurpose drugs for the treatment of Peyronie’s disease (PD). PD is a fibrotic disease characterised by c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilg, Marcus M., Lapthorn, Alice R., Ralph, David J., Cellek, Selim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744312/
https://www.ncbi.nlm.nih.gov/pubmed/36508413
http://dx.doi.org/10.1371/journal.pone.0277646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744312/
https://www.ncbi.nlm.nih.gov/pubmed/36508413
http://dx.doi.org/10.1371/journal.pone.0277646

Ejemplares similares